Dr. Brad McGregor

I mean, it's pretty small numbers, but it's pretty remarkable.

So I do think this is, we're definitely able to do far more now than we could before.

but not enough, right?

And so I think as we look at this, there's two questions.

One, how can we make ED Pembroke even better?

And so I think there's efforts underway to do that.

And then the second one is, what do we do if ED Pembroke doesn't work, right?

What do we do in that post-ED Pembroke setting?

That's really a data-free zone right now, and that was a lot of opportunities.

I mean, I think to that point, I think it's really important.

You know, these patients here are two days out of two weeks out of three weeks.

And it's important to always be asking for neuropathy, right?

So I think the most effective strategy is hold and dose reduction.

And if you wait to get to bad grade two, you're not going to be going back, right?

So I think...

As Amanda said, educate those patients early on.

And I have no problems independent of scans or CTDA or any of the above.

If they're having toxicities, you know, this is palliative therapy, even though we think we can care patients, but we don't want to make them miserable.

at the expense of trying to make the next scan look a little bit better.

So I think it is really important to dose reduce.